Trial Profile
Phase II Trial of Dasatinib in Advanced (Stage IIIB/IV) Squamous Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 05 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Dec 2011 New trial record